Incheon, South Korea and Zug, Switzerland -- September 01, 2026 -- Samsung Biologics, through its Swiss subsidiary Samsung Peptide AG, published the formal tender offer prospectus for PolyPeptide Group AG, setting a cash price of CHF 44.31 per share and an implied equity value of approximately CHF 1.46 billion. The filing, made in Zug, Switzerland, follows a pre-announcement issued July 20, 2026, and covers all publicly held shares of the peptide-focused contract manufacturer listed on the SIX Swiss Exchange. The main acceptance period runs from Sept. 15 to Oct. 12, 2026.
The CHF 44.31 price carries a 40% premium over PolyPeptide's unaffected share price recorded on April 10, 2026, the last trading day before acquisition speculation surfaced. Measured against the 60-day volume-weighted average price ahead of the July pre-announcement, the premium narrows to 11.6%.
Draupnir Holding Commits Its Full 55.65% Stake to the Offer
Draupnir Holding B.V., PolyPeptide's largest individual shareholder with roughly 55.65% of shares outstanding excluding treasury shares, has agreed to tender its entire position into the deal. PolyPeptide's independent, non-conflicted board members unanimously recommended shareholders accept the offer, a stance backed by an independent fairness opinion from IFBC AG.
Offer Requires 662⁄3% Acceptance on a Fully Diluted Basis
Samsung Peptide set a minimum acceptance threshold of 662⁄3% of PolyPeptide shares on a fully diluted basis, excluding treasury shares, alongside customary regulatory approvals. A ten-trading-day cooling-off period on the SIX Swiss Exchange runs from Sept. 1, 2026, before shareholders can formally tender, under Swiss takeover law. Samsung Biologics expects the transaction to close by the end of 2026.
Samsung Peptide Plans Squeeze-Out and Delisting After Settlement
Once the offer settles, Samsung Peptide intends to pursue a squeeze-out of remaining minority shareholders and delist PolyPeptide shares from the SIX Swiss Exchange. The acquisition would bring PolyPeptide's six GMP-certified peptide manufacturing sites across Europe, the U.S. and India into Samsung Biologics' network, which already operates 845,000 liters of biomanufacturing capacity across facilities in Korea and Rockville, Maryland.
PolyPeptide's GLP-1 Manufacturing Base Adds to Deal Rationale
PolyPeptide, whose peptide manufacturing history dates to 1952, supplies active pharmaceutical ingredients for metabolic disease treatments, including GLP-1 therapies, to pharma and biotech customers globally. Its shares trade under ticker PPGN on the SIX Swiss Exchange.
Sodali, mandated as information agent for the transaction, operates separate hotlines for institutional investors at +44 204 5136928 and retail shareholders at +41 43 550 72 52.